Literature DB >> 27791524

Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas.

Hazem M Negm1,2, Rafid Al-Mahfoudh1,3, Manish Pai1,4, Harminder Singh1,5, Salomon Cohen1,6, Sivashanmugam Dhandapani1,7, Vijay K Anand8, Theodore H Schwartz1,8,9.   

Abstract

OBJECTIVE Regrowth of the lesion after surgical removal of pituitary adenomas is uncommon unless subtotal resection was originally achieved in the first surgery. Treatment for recurrent tumor can involve surgery or radiotherapy. Locations of residual tumor may vary based on the original approach. The authors evaluated the specific sites of residual or recurrent tumor after different transsphenoidal approaches and describe the surgical outcome of endoscopic endonasal transsphenoidal reoperation. METHODS The authors analyzed a prospectively collected database of a consecutive series of patients who had undergone endoscopic endonasal surgeries for residual or recurrent pituitary adenomas after an original transsphenoidal microscopic or endoscopic surgery. The site of the recurrent tumor and outcome after reoperation were noted and correlated with the primary surgical approach. The chi-square or Fisher exact test was used to compare categorical variables, and the Mann-Whitney U-test was used to compare continuous variables between surgical groups. RESULTS Forty-one patients underwent surgery for residual/recurrent pituitary adenoma from 2004 to 2015 at Weill Cornell Medical College. The previous treatment was a transsphenoidal microscopic (n = 22) and endoscopic endonasal (n = 19) surgery. In 83.3% patients (n = 30/36) there was postoperative residual tumor after the initial surgery. A residual tumor following endonasal endoscopic surgery was less common in the sphenoid sinus (10.5%; 2/19) than it was after microscopic transsphenoidal surgery (72.7%; n =16/22; p = 0.004). Gross-total resection (GTR) was achieved in 58.5%, and either GTR or near-total resection was achieved in 92.7%. Across all cases, the average extent of resection was 93.7%. The rate of GTR was lower in patients with Knosp-Steiner Grade 3-4 invasion (p < 0.0005). Postoperative CSF leak was seen in only one case (2.4%), which stopped with lumbar drainage. Visual fields improved in 52.9% (n = 9/17) of patients and were stable in 47% (n = 8/17). Endocrine remission was achieved in 77.8% (n = 14/18) of cases, 12 by surgery alone and 2 by adjuvant medical (n = 1) and radiation (n = 1) therapy. New diabetes insipidus occurred in 4.9% (n = 2/41) of patients-in one of whom an additional single anterior hormonal axis was compromised-and 9.7% (n = 4/41) of patients had a new anterior pituitary hormonal insufficiency. CONCLUSIONS Endonasal endoscopic reoperation is extremely effective at removing recurrent or residual pituitary adenomas that remain after a prior surgery, and it may be preferable to radiation therapy particularly in symptomatic patients. Achievement of GTR is less common when lateral cavernous sinus invasion is present. The locations of residual/recurrent tumor were more likely sphenoidal and parasellar following a prior microscopic transsphenoidal surgery and sellar following a prior endonasal endoscopic surgery.

Entities:  

Keywords:  ACTH = adrenocorticotropic hormone; DI = diabetes insipidus; EOR = extent of resection; FSH = follicle-stimulating hormone; GH = growth hormone; GTR = gross-total resection; IGF-1 = insulin-like growth factor 1; LH = luteinizing hormone; PRL = prolactin; TSH = thyroid-stimulating hormone; adenoma; craniotomy; endonasal endoscopic; pituitary surgery; pituitary tumor; reoperation; skull base; transsphenoidal

Mesh:

Year:  2016        PMID: 27791524     DOI: 10.3171/2016.8.JNS152709

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Utility of intraoperative ultrasonography for resection of pituitary adenomas: a comparative retrospective study.

Authors:  Mohammed Alshareef; Stephen Lowe; Yeonhee Park; Bruce Frankel
Journal:  Acta Neurochir (Wien)       Date:  2021-01-05       Impact factor: 2.216

2.  Association of NM23 polymorphisms and clinicopathological features and recurrence of invasive pituitary adenomas.

Authors:  Hua Wang; Wenyuan Sang
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

3.  Cerebrospinal Fluid Leak after Transsphenoidal Surgery: A Systematic Review and Meta-analysis.

Authors:  Emma M H Slot; Rengin Sabaoglu; Eduard H J Voormolen; Eelco W Hoving; Tristan P C van Doormaal
Journal:  J Neurol Surg B Skull Base       Date:  2021-08-20

4.  Outcome of Endoscopic Transsphenoidal Surgery for Recurrent or Residual Pituitary Adenomas and Comparison to Non-Recurrent or Residual Cohort by Propensity Score Analysis.

Authors:  Xuan Gong; Yang Zhuo; Huichun Yuan; Kui Yang; Chuntao Li; Songshan Feng; Mingyu Zhang; Zhenyan Li; Hongshu Zhou; Zhixiong Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

Review 5.  Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature.

Authors:  Elizabeth Ogando-Rivas; Andrew F Alalade; Jerome Boatey; Theodore H Schwartz
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

6.  Comparative study of complications after primary and revision transsphenoidal endoscopic surgeries.

Authors:  Leandro Custódio do Amaral; Baltazar Leão Reis; Antônio Ribeiro-Oliveira; Thamires Marx da Silva Santos; Alexandre Varella Giannetti
Journal:  Neurosurg Rev       Date:  2020-08-11       Impact factor: 3.042

Review 7.  Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.

Authors:  Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

8.  The outcome of TSHoma from a tertiary care institute in India.

Authors:  Aditya Dutta; Nimisha Jain; Ashutosh Rai; Rahul Gupta; Sivashanmugam Dhandapani; Anil Bhansali; Bishan Das Radotra; Chirag Kamal Ahuja; Pinaki Dutta
Journal:  Surg Neurol Int       Date:  2021-04-14

Review 9.  Clinical relevance of tumor consistency in pituitary adenoma.

Authors:  Alberto Acitores Cancela; Víctor Rodríguez Berrocal; Héctor Pian; Juan Salvador Martínez San Millán; Juan José Díez; Pedro Iglesias
Journal:  Hormones (Athens)       Date:  2021-06-19       Impact factor: 2.885

10.  A Case of Giant Pituitary Adenoma Associated with a Postoperative Mental Disorder That Ultimately Resulted in Bilateral Blindness.

Authors:  Masahiro Tonari; Yuko Nishikawa; Junko Matsuo; Masashi Mimura; Hidehiro Oku; Jun Sugasawa; Naokado Ikeda; Yoshitaka Kurisu; Tsunehiko Ikeda
Journal:  Case Rep Ophthalmol       Date:  2020-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.